# About Sermorelin Get: An Independent Editorial Digest of the Research

> About Sermorelin Get — an independent editorial project that publishes cited summaries of the peer-reviewed sermorelin (GHRH(1-29)) literature. Not a clinic, not a pharmacy, not a vendor.

An independent editorial project that clips the published sermorelin literature to one board and cites every finding to its source.

## What this site is

Sermorelin Get is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin (GHRH(1-29)). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The format is deliberate: a research zine, a corkboard of clipped studies. Each finding is pinned to the paper it came from, the strong results and the open gaps kept side by side, and the speculative frontier material flagged as provisional rather than dressed up as fact. We would rather show you the seams — the off-register print, the torn corner, the empty clipping where the adult-safety data should be — than hand you a seamless story the evidence doesn't support.

## About the word 'Get'

The name needs a plain word about its plain word. *Get* here means *acquire the literature* — find it, read it, file it where you can see it. It is the verb of a reader assembling a board, not a checkout button. There is no storefront on this site, no cart, no price, no order form. We do not sell sermorelin, source it, or point you to anyone who does. Nothing here is dosed, dispensed, or sold.

The modifier is editorial framing — a position this publisher takes relative to the literature, not a claim about services. Read the board; that is the whole transaction.

## How we handle the research

Three rules govern every page. First, attribution: every quantitative claim is tied to a specific cited study, and findings from the stabilized analog tesamorelin or the broader GHRH-analog class are labeled as such, never folded into sermorelin's own record. Second, accuracy on the regulatory history: sermorelin was formerly FDA-approved for pediatric growth-hormone deficiency, withdrawn in 2008 for commercial reasons, and is now compounded under FDA's interim 503A policy — we state that as filed, neither inflating it to 'currently approved' nor dismissing it as 'never approved.' Third, no human dosing: we describe what studies administered, to which species, by which route, and we never translate that into a recommendation. The compound is also prohibited in sport under the WADA list.

---

A corkboard reading of the sermorelin literature, riso-clipped and red-strung — every GHRH(1-29) finding pinned to the study that measured it, the body-composition data taped where it belongs as tesamorelin, the frontier wound-healing and oncology signals stamped provisional, and the torn-open clipping where the adult-safety evidence runs out left in plain view; 'get' here means get the literature, and nothing on this board is dosed, dispensed, or sold.